



## Evaluating the impact of infliximab use on surgical outcomes in pediatric Crohn's disease ☆☆☆☆☆



Paulette I. Abbas<sup>a,b</sup>, Michelle L. Peterson<sup>a,b</sup>, Sara C. Fallon<sup>a,b</sup>, Monica E. Lopez<sup>a,b</sup>, David E. Wesson<sup>a,b</sup>, Seema M. Walsh<sup>a,c</sup>, Richard Kellermayer<sup>a,c</sup>, J. Ruben Rodriguez<sup>a,b,\*</sup>

<sup>a</sup> Texas Children's Hospital, Baylor College of Medicine, Houston, Texas

<sup>b</sup> The Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas

<sup>c</sup> Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Baylor College of Medicine, Houston, Texas

### ARTICLE INFO

#### Article history:

Received 24 January 2016

Accepted 7 February 2016

#### Key words:

Pediatric surgery  
Pediatric gastroenterology  
Crohn's disease  
Infliximab  
Surgical recurrence

### ABSTRACT

**Background:** The impact of infliximab (IFX) on surgical outcomes is poorly defined in pediatric Crohn's disease (CD). We evaluated our institution's experience with IFX on postoperative complications and surgical recurrence. **Methods:** A retrospective review of children who underwent intestinal resection with primary anastomosis for CD from 1/2002 to 10/2014 was performed. Data collected included IFX use and surgical outcomes. Preoperative IFX use was within 3 months of surgery.

**Results:** Seventy-three patients were included with median age 15 years (range: 9–18). The most frequent indications for operation were obstruction (n = 26) and fistulae (n = 19). Nine patients (13%) had a surgical recurrence at a median of 2.3 years (IQR 0.7–3.5). Twenty-two patients received preoperative IFX at median of 26 days (IQR 14–46). There were 7 postoperative complications: 2 bowel obstructions, and 5 superficial wound infections. Outcomes of patients stratified by IFX were not different. When stratified by indication, refractory disease was associated with higher preoperative IFX use (IFX use 55% vs. no IFX use 28%, p = 0.027). No specific indication was associated with increased reoperation rates.

**Conclusion:** Pediatric CD patients treated with preoperative IFX undergo intestinal resection with primary anastomosis with acceptable morbidity. The heterogeneous approach to medical management underscores the need for guidelines to direct treatment.

© 2016 Elsevier Inc. All rights reserved.

### 1. Background

The medical and surgical management of patients with Crohn's disease (CD) is complex and continually evolving with advances in therapy. While up to 70% of patients will require surgical intervention for treatment of Crohn's disease [1,2], the perioperative medical management plays a large role in influencing postoperative clinical course. Thus, medical and surgical therapies for Crohn's disease are closely intertwined and ideal therapy should aim to optimize both methods of treatment. Recent integration of infliximab (IFX), an anti-TNF alpha immunomodulator, into the medical regimen has positively impacted patients' clinical course through prolonged periods of remission [3–6].

☆ Level of Evidence: 2b.

☆☆ Contributors Statement: Dr. Paulette I. Abbas, Dr. Richard Kellermayer, and Dr. J. Ruben Rodriguez conceptualized and designed the study, drafted the initial manuscript, reviewed and revised the manuscript, and approved the final manuscript as submitted. Ms. Michelle L. Peterson, Dr. Sara C. Fallon, Dr. Monica E. Lopez, Dr. David E. Wesson, and Dr. Seema M. Walsh reviewed and revised the manuscript for critical intellectual content and approved the final manuscript as submitted.

☆☆☆ Disclosures: The authors have no disclosures of funding or financial support to disclose with regard to the preparation of this manuscript.

\* Corresponding author at: Texas Children's Hospital, 6701 Fannin Street, Suite 1210, Houston, Texas 77030. Tel.: +1 832 822 3135; fax: +1 832 825 3141.

E-mail address: [rxrodri2@texaschildrens.org](mailto:rxrodri2@texaschildrens.org) (J.R. Rodriguez).

Consequently, it was frequently prescribed to patients with moderate to severe Crohn's disease. However, there have been reports associating the use of IFX increasing postoperative complications [7–10].

While multiple large studies have been performed in adults to evaluate the effectiveness and complications of infliximab infusion in Crohn's disease, there is limited literature on the use of IFX in children or surgical outcomes related to IFX in children. Particularly, the effects of IFX in the perioperative and postoperative period following an intestinal resection are rarely described in the pediatric literature. To address this gap, we sought to evaluate our institutional experience with infliximab after intestinal resection in pediatric Crohn's disease. Predominantly, we aimed to evaluate postoperative surgical and wound complications as well as rate of reoperation in relation to IFX use.

### 2. Methods

#### 2.1. Patient population

After institutional review board approval (H-31167), all children (≤18 years of age) with Crohn's disease who underwent initial intestinal resection with primary anastomosis at a single large referral center from January 2002 to October 2014 were included. Patients were identified through billing ICD-9 codes for Crohn's disease and chart reviews

were conducted to confirm diagnosis of Crohn's disease via pathology reports. Patients with isolated perianal Crohn's disease, patients left in gastrointestinal discontinuity or with an enterostomy, and isolated stricturoplasties were excluded. In the majority of cases, the operative technique used was the laparoscopic approach with primarily extracorporeal stapled anastomosis through the umbilical port.

## 2.2. Infliximab administration

The pediatric gastroenterologist prescribed infliximab infusions to patients with moderate to severe Crohn's based on clinical criteria. When prescribed, IFX was typically administered every 8 weeks for a length of time that was to the discretion of the physician. For the purposes of our study, we defined preoperative administration of IFX use within 12 weeks of surgery as that is frequently the threshold described in literature [8,9,11]. Postoperative IFX infusion was also documented.

## 2.3. Study design and clinical variables of interest

This study is a retrospective chart review evaluating the impact of IFX on surgical outcomes after intestinal resection for Crohn's disease. Data collected included patient demographics, nutritional status at operation, disease details, perioperative steroid use, information on Infliximab infusion, and surgical outcomes. Nutritional status was determined through perioperative albumin and prealbumin levels. Details of the disease included location, perforating versus nonperforating disease, presenting symptoms, and indication for resection (obstruction, fistula, refractory disease). Surgical outcomes included long-term surgical recurrence defined as the need for a second surgical intervention in the same segment of bowel as the site of previous resection as well as postoperative complications. Postoperative surgical complications included superficial, deep and organ space surgical site infections, wound dehiscence, anastomotic leak, and small bowel obstruction occurring within 30-days of surgery. Long-term surgical recurrence was determined by following patients through to their most recent clinic visit.

## 2.4. Statistical analyses

Statistical analyses were performed using SPSS (Version 22.0, SPSS Inc., Armonk, NY). Univariate analyses were performed to evaluate the association between preoperative and postoperative IFX exposure and surgical outcomes (recurrence and postoperative complications). IFX exposure was further subdivided into four categories (preoperative IFX only, postoperative IFX only, both preoperative and postoperative IFX, and IFX-naïve). Continuous variables were analyzed using Student's t-test or Mann-Whitney-U, depending on data normality. One-way ANOVA was performed to compare means among multiple groups. Frequency distributions between categorical values were compared using  $\chi^2$ -analysis. A p-value of <0.05 was deemed statistically significant.

## 3. Results

### 3.1. Patient characteristics and outcomes

Seventy-three patients met inclusion criteria at a median age of 15 years (range 9–18). 55% (n = 40) were males and mean weight at time of surgery was  $47 \pm 11.8$  kg with median weight percentile of 10.8% (IQR 1.9–36.4). All patients underwent an intestinal resection and the most frequent resection was an ileocectomy (n = 41). The indications for operation include obstructive symptoms (n = 35), fistulizing disease (n = 26), and refractory disease (n = 12). Sixteen patients (22%) had perforating disease identified intraoperatively. Sixty-nine patients (95%) had clinical follow-up over a median of 1.8 years (IQR 0.5–3.8). Seven patients had postoperative complications; five had superficial surgical site infections (SSI) successfully managed with

antibiotics and two had small bowel obstruction managed nonoperatively. No patient developed deep/organ surgical site infection or anastomotic leak. Nine patients developed recurrence requiring a second abdominal operation at a median of 2.3 years (IQR 0.7–3.5) postoperatively.

### 3.2. Infliximab infusion

Twenty-four patients (33%) received preoperative IFX infusion at a median of 26 days (IQR 14–46) prior to their index operation. Twenty-six patients received postoperative IFX infusion beginning at a median time of 177 days (IQR 41–370) after surgery. The decision to place patients on postoperative IFX was determined through provider preference and indications varied among the gastroenterology providers. Twelve patients received both preoperative and postoperative IFX infusions.

### 3.3. Surgical outcomes stratified by infliximab exposure

Patients who received infusion of IFX prior to surgical resection (n = 22) were younger but had similar nutritional status and perioperative steroid use when compared to their counterparts who did not receive IFX (n = 51) (Table 1). Perioperative IFX did not significantly increase risk of postoperative complications nor did it decrease rate of recurrence or length of time to recurrence.

When stratified by postoperative IFX exposure, the 26 patients who received IFX after the surgery had no significant increase in long-term surgical recurrence rates (Table 2). Further subanalysis of the impact of postoperative IFX exposure in the nine patients with surgical recurrence revealed no significant difference in the time to recurrence between those who received postoperative IFX (n = 5) and those who did not (n = 4) (6.7 months (range 4.8–37) vs. 5.3 months (range 0.8–42), p = 0.456). All patients who developed a recurrence were adolescents (range 12.9–17.4 years) and most (n = 6) had obstructive etiology; none of the surgical recurrences had intraoperative identification of perforating disease at time of index resection and anastomosis.

Further evaluation of exact IFX treatment regimen revealed no differences in patient characteristics, nutritional status, or postoperative complications among the four groups (Table 3). The rate of surgical recurrence of Crohn's was equivalent among patient groups (Fig. 1).

## 4. Discussion

In this retrospective review of pediatric Crohn's disease, we evaluated the outcomes of children who underwent intestinal resection and analyzed surgical recurrence stratified by infliximab (IFX) use. We also assessed the possible effect of IFX use on postoperative complications. Our study revealed no significant difference in rate of surgical

**Table 1**

Patient characteristics, preoperative nutritional and medication status, and surgical outcomes stratified by preoperative Infliximab use.

Variables	Preoperative IFX (n = 22)	No IFX (n = 51)	p-value
Age (years), median (IQR)	15.1 (13.4–16.9)	16.8 (14.8–18)	<b>0.008</b>
Male gender, n (%)	13 (59)	27 (53)	0.628
Weight percentile at time of surgery, median (IQR)	4.43 (1.9–20.0)	14.6 (1.5–45.4)	0.418
Perioperative steroid use, n (%)	11 (50)	29 (57)	0.589
Albumin at time of operation, median (IQR)	3.9 (2.9–4.8)	3.4 (3.0–3.8)	0.176
Prealbumin at time of operation, median (IQR)	19.0 (8.6–19)	19.6 (11.1–27.1)	0.600
Perforating disease, n (%)	4 (18)	12 (24)	0.612
Postoperative complications, n (%)	2 (9)	5 (10)	0.924
Reoperation for recurrence, n (%)	2 (9)	7 (14)	0.562
Time to reoperation (years), median (range)	1.3 (0.6–2.1)	2.9 (0.3–5.0)	0.333

**Table 2**  
Patient characteristics and surgical outcomes in pediatric Crohn's disease patients stratified by postoperative Infliximab use.

Surgical outcomes	Postoperative IFX (n = 26)	No IFX (n = 47)	p-value
Age, years, median (IQR)	15.9 (14.6–17.5)	16.4 (14.3–17.8)	0.773
Male gender, n (%)	14 (54)	26 (55)	0.904
Weight percentile at time of surgery, median (IQR)	7.2 (0.8–35.4)	13.5 (4.1–35.5)	0.380
Perforating disease, n (%)	6 (23)	10 (21)	0.859
Postoperative complications, n (%)	2 (8)	5 (11)	0.682
Reoperation for recurrence, n (%)	5 (19)	4 (9)	0.194
Time to reoperation (years), median (range)	2.1 (0.6–5.0)	2.7 (0.3–3.7)	0.905

recurrence between IFX-exposed and IFX-naive patients. Furthermore, IFX exposure did not alter time to surgical recurrence. Similarly, the presence of IFX in the preoperative or postoperative period did not increase the rate of postoperative complications. There were only five patients with wound complications and no patient with anastomotic complications, a low complication rate in a cohort of patients who are at high risk for developing postoperative complications.

Previous studies evaluating the impact of IFX on surgical complications were primarily performed in adults and yielded mixed results. While some studies suggest that IFX in the perioperative period was associated with worse outcomes, particularly with regard to wound complications [7,10], others found no significant increase in the risk of complications when administering IFX [11,12]. A majority of these studies exclusively evaluate preoperative IFX use in association with postoperative events. Lau et al. reviewed the serum levels of IFX a week prior to surgery and identified an association between higher levels of IFX detected in the serum and postoperative infectious complications. A study by Ali et al. also demonstrated higher rates of wound infection with postoperatively administered anti-TNF alpha medications [9]. A meta-analysis by Kopylov et al. of 8 studies, exclusive of the previous two studies, further confirmed a significant increase in infectious complications after preoperative exposure to IFX [10]. Conversely, Kunitake et al. determined that preoperative IFX administration within 12 weeks of surgery did not alter infectious or wound complications [11] and a meta-analysis by Yang et al. reached a similar conclusion [8]. The differences among results from the meta-analyses highlight the inconsistencies of the literature available and the need for refined definitions of postoperative complications. Our data support the latter findings with no significant increase in wound or infectious complications in children managed preoperatively with IFX.

While most data from the literature focus on preoperative IFX use, postoperative exposure may also impact outcomes. Regueiro et al. reviewed the effects of postoperative IFX on adverse events 1 year after surgery and found that IFX did not increase the likelihood of complications of anastomotic leak, infectious complications, or death [12]. Our study supports these findings in children as those who received

postoperative IFX, either in isolation or in conjunction with preoperative IFX, did not have a significantly higher rate of postoperative complications.

The findings with regard to the effect of postoperative IFX use on surgical recurrence are similarly mixed. In the adult literature, postoperative IFX has been shown to decrease recurrence rates and protract the time to recurrence. Multiple prospective randomized clinical trial in adults have demonstrated better prevention of clinical, serologic, and endoscopic recurrence with IFX after intestinal resection [3,13,14]; however, the literature on the impact of IFX on surgical recurrence is limited. A study by Regueiro et al. revealed that postoperative IFX use in adults with CD after intestinal resection had a longer time to both endoscopic recurrence and time to subsequent surgery [6]. Similarly, the ACCENT 1 study, a large randomized controlled trial comparing placebo to maintenance IFX therapy in active Crohn's disease in adults, revealed a higher rate of clinical remission up to 54 weeks when IFX was administered [15]. Although the data in adults are promising, similar results have not been demonstrated in children. Bobanga et al. showed equivocal outcomes in clinical recurrence in children managed with immunomodulation prophylaxis and hypothesized that differences in outcomes between adults and children might be secondary to children presenting with a more aggressive disease phenotype [16]. Our data similarly demonstrate that the presence of IFX in the postoperative period, as well as the preoperative period, did not significantly impact surgical recurrence or time to reoperation.

Our results provide some insight into the postoperative course for pediatric surgical CD patients managed with perioperative IFX. Limitations to this study include a relatively small number of patients treated with IFX who underwent surgery. Furthermore, we could not describe histologic or endoscopic recurrence in our cohort as a protocol for endoscopic surveillance and histologic scoring has not been standardized in the postoperative period at our institution. Additionally, the average follow-up period was short, which introduces the possibility of missing a late or delayed recurrence. Lastly, the medical management of Crohn's is complex and IFX was often administered in conjunction with other medications with regimens being provider-dependent. We were unable to categorize the exact perioperative medical management for each patient or group him or her in a meaningful manner for comparison. This was owing to variation in perioperative medical therapy and the heterogeneity in the timing or progression of medical management.

While our data suggest that preoperative IFX may be administered without adversely impacting a successful anastomosis or conferring additional risk of postoperative complications, prospective studies are warranted to validate these findings. It is important to emphasize that, before any such study can begin, a standard approach to the medical management of pediatric Crohn's disease must be adopted. Many other studies attempt such comparisons but are limited in their conclusions owing to confounding use of other immunomodulators, such as methotrexate, azathioprine and steroids. As such, there has been a call to standardize these treatment modalities [17]. The variability in medication treatment and surveillance techniques must be addressed

**Table 3**  
Patient characteristics, preoperative nutritional and medication status, and surgical outcomes based on exact exposure to IFX.

Variables	Preoperative IFX only (n = 10)	Postoperative IFX only (n = 14)	Preoperative and postoperative IFX (n = 12)	IFX-naive (n = 37)	p-value
Age, years, median (IQR)	13.9 (13–16)	17 (14.6–18.1)	15.2 (13.9–17)	16.8 (15.1–18)	0.051
Male gender, n (%)	5 (50)	6 (43)	8 (67)	21 (57)	0.651
Weight percentile at time of surgery, median (IQR)	4.4 (3.5–25)	10 (0–45.9)	4.4 (1.0–15.6)	16.3 (4.0–40.8)	0.456
Perioperative steroid use, n (%)	5 (50)	9 (64)	6 (50)	20 (54)	0.868
Albumin at time of operation, median (IQR)	4.3 (3.6–4.8)	3.5 (3.2–4.0)	3.4 (2.6–4.2)	3.2 (2.7–3.6)	0.123
Prealbumin at time of operation, median (range)	–	20.0 (11.2–28.8)	19.0 (8.6–22.1)	19.6 (9.9–36.5)	0.782
Perforating disease, n (%)	2 (20)	4 (29)	2 (17)	8 (22)	0.901
Postoperative complications, n (%)	1 (10)	1 (7)	1 (8)	4 (11)	0.980
Reoperation for recurrence, n (%)	0 (0)	3 (21)	2 (17)	4 (11)	0.440
Time to reoperation (years), median (range)	–	2.9 (0.81–5.0)	1.3 (0.59–2.1)	2.7 (0.29–3.7)	0.472




Fig. 1. Infliximab treatment in our pediatric cohort.

through multidisciplinary consortiums between pediatric gastroenterologists and pediatric surgeons to develop a protocol for the safe and effective management of this complex patient population. This study highlights the need for the development of institutional practice guidelines for the medical treatment and postoperative surveillance of pediatric Crohn's disease.

## References

- [1] Watanabe T, Sasaki I, Sugita A, et al. Interval of less than 5 years between the first and second operation is a risk factor for a third operation for Crohn's disease. *Inflamm Bowel Dis* 2012;18:17–24.
- [2] Simillis C, Yamamoto T, Reese GE, et al. A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease. *Am J Gastroenterol* 2008;103:196–205.
- [3] Yoshida K, Fukunaga K, Ikeuchi H, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. *Inflamm Bowel Dis* 2012;18:1617–23.
- [4] Scott FI, Osterman MT. Medical management of Crohn disease. *Clin Colon Rectal Surg* 2013;26:67–74.
- [5] Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. *Gastroenterology* 2009;136:441–50.
- [6] Regueiro M, Kip KE, Baidoo L, et al. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence. *Clin Gastroenterol Hepatol* 2014;12:1494–502.
- [7] Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFalpha therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. *Ann Surg* 2015;261:487–96.
- [8] Yang ZP, Hong L, Wu Q, et al. Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis. *Int J Surg* 2014;12:224–30.
- [9] Ahmed Ali U, Martin ST, Rao AD, et al. Impact of preoperative immunosuppressive agents on postoperative outcomes in Crohn's disease. *Dis Colon Rectum* 2014;57:663–74.
- [10] Kopylov U, Ben-Horin S, Zmora O, et al. Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. *Inflamm Bowel Dis* 2012;18:2404–13.
- [11] Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. *J Gastrointest Surg* 2008;12:1730–6.
- [12] Regueiro M, El-Hachem S, Kip KE, et al. Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease. *Dig Dis Sci* 2011;56:3610–5.
- [13] Armuzzi A, Felice C, Papa A, et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. *J Crohns Colitis* 2013;7:623–9.
- [14] Yamamoto T. Prevention of recurrence after surgery for Crohn's disease: efficacy of infliximab. *World J Gastroenterol* 2010;16:5405–10.
- [15] Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet* 2002;359:1541–9.
- [16] Bobanga ID, Bai S, Swanson MA, et al. Factors influencing disease recurrence after ileocolic resection in adult and pediatric onset Crohn's disease. *Am J Surg* 2014;208:591–6.
- [17] Lamore RF, Hechenbleikner EM, Ha C, et al. Perioperative glucocorticoid prescribing habits in patients with inflammatory bowel disease: a call for standardization. *JAMA Surg* 2014;149:459–66.